Cargando…

Beyond Glioma: The Utility of Radiomic Analysis for Non-Glial Intracranial Tumors

SIMPLE SUMMARY: Tumor qualities, such as growth rate, firmness, and intrusion into healthy tissue, can be very important for operation planning and further treatment. Radiomics is a promising new method that allows the determination of some of these qualities on images performed before surgery. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalasauskas, Darius, Kosterhon, Michael, Keric, Naureen, Korczynski, Oliver, Kronfeld, Andrea, Ringel, Florian, Othman, Ahmed, Brockmann, Marc A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834271/
https://www.ncbi.nlm.nih.gov/pubmed/35159103
http://dx.doi.org/10.3390/cancers14030836
Descripción
Sumario:SIMPLE SUMMARY: Tumor qualities, such as growth rate, firmness, and intrusion into healthy tissue, can be very important for operation planning and further treatment. Radiomics is a promising new method that allows the determination of some of these qualities on images performed before surgery. In this article, we provide a review of the use of radiomics in various tumors of the central nervous system, such as metastases, lymphoma, meningioma, medulloblastoma, and pituitary tumors. ABSTRACT: The field of radiomics is rapidly expanding and gaining a valuable role in neuro-oncology. The possibilities related to the use of radiomic analysis, such as distinguishing types of malignancies, predicting tumor grade, determining the presence of particular molecular markers, consistency, therapy response, and prognosis, can considerably influence decision-making in medicine in the near future. Even though the main focus of radiomic analyses has been on glial CNS tumors, studies on other intracranial tumors have shown encouraging results. Therefore, as the main focus of this review, we performed an analysis of publications on PubMed and Web of Science databases, focusing on radiomics in CNS metastases, lymphoma, meningioma, medulloblastoma, and pituitary tumors.